Why did VERU's Q3 2024 earnings exceed forecasts significantly?

Veru's Q3 2024 earnings exceeded forecasts significantly due to a combination of factors: 1. **Revenue Growth**: Veru reported a total revenue of $3.95 million for Q3 2024, which represents an 18% increase from the same quarter in the previous year. This growth was primarily driven by the company's focus on its clinical trials and drug development programs. 2. **Enobosarm Clinical Trials**: The company's ongoing clinical trials, including the Phase 2b QUALITY study of enobosarm for obesity, have contributed significantly to its revenue growth. Enobosarm is a novel oral selective androgen receptor modulator (SARM) that has shown promising results in treating muscle loss associated with weight loss drugs. 3. **Market Demand for Antiviral Drugs**: The global demand for antiviral drugs, particularly in the context of the COVID-19 pandemic, has created a significant market opportunity for Veru's drugs, such as NV-387. Although Veru's primary focus is not directly on COVID-19 treatments, the overall demand for antiviral drugs has likely contributed to the company's revenue growth. 4. **Strategic Collaborations**: Veru's collaboration with Eli Lilly and Company for the trial of enobosarm in the 3rd line treatment of AR+ER+HER2- metastatic breast cancer has also been a key factor in its revenue generation. In summary, Veru's Q3 2024 earnings exceeded forecasts significantly due to a combination of revenue growth from clinical trials, market demand for antiviral drugs, and strategic collaborations.